{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:04:02Z","timestamp":1784783042082,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to comprehensively evaluate the predictive value of prognostic nutritional index (PNI) for long-term survival in non-small cell lung cancer (NSCLC) patients treated with programmed death receptor-1 and its ligand (PD-1\/PD-L1) inhibitors through systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library databases up to January 2026. Observational studies assessing the association between PNI and survival outcomes in NSCLC patients treated with PD-1\/PD-L1 inhibitors were included. Two investigators independently performed literature screening, data extraction, and methodological quality assessment (using the Newcastle-Ottawa Scale). Heterogeneity was assessed using the pooled hazard ratio (HR) and its 95% confidence interval (CI) in a random-effects model, and subgroup analyses, sensitivity analyses, and publication bias assessments were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14 studies involving 2,106 patients were included. Meta-analysis results showed that a higher PNI was associated with significantly improved overall survival (OS) (HR\u202f=\u202f0.46, 95% CI: 0.34\u20130.64,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.00001) and progression-free survival (PFS) (HR\u202f=\u202f0.63, 95% CI: 0.52\u20130.76, p\u202f&amp;lt;\u202f0.00001). Subgroup analysis indicated that the prognostic value of PNI remained consistent regardless of study region (China, Turkey, Japan, UK) or PNI cutoff value (&amp;gt;45 or \u226445). OS analysis showed high heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f89%), but sensitivity analysis results were robust. Publication bias assessment suggested publication bias in OS, but after correction using pruning and complementation, the significant association between PNI and OS remained unchanged (corrected HR: 0.47, 95% CI: 0.34\u20130.64).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests an association between higher baseline PNI and improved survival outcomes in NSCLC patients receiving PD-1\/PD-L1 inhibitor therapy. The PNI may serve as a candidate biomarker for risk stratification, but its clinical utility requires validation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1859449","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:28:22Z","timestamp":1784780902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1\/PD-L1 inhibitors: a meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ping","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, The Third People\u2019s Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoke","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Provincial Construction Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third People\u2019s Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Hospital and Clinical Medical College of Chengdu University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhumei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third People\u2019s Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1779081","DOI":"10.3389\/fonc.2026.1779081","article-title":"Immune checkpoint inhibitors in resectable non-small cell lung cancer: recent successes and ongoing challenges","volume":"16","author":"Abodunrin","year":"2026","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.21037\/tlcr-2026-1-0018","article-title":"Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions","volume":"15","author":"Liang","year":"2026","journal-title":"Transl Lung Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e260017","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Riely","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103578","DOI":"10.1016\/j.jtho.2026.103578","article-title":"The optimization of radiotherapy in lung Cancer treatment: 20 years of Progress","volume":"21","author":"Salama","year":"2026","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1809450","DOI":"10.3389\/fonc.2026.1809450","article-title":"Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis","volume":"16","author":"Luo","year":"2026","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"189587","DOI":"10.1016\/j.bbcan.2026.189587","article-title":"Immunosenescence in elderly patients with advanced non-small cell lung cancer: mechanisms and therapeutic implications","volume":"1881","author":"Wang","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"105216","DOI":"10.1016\/j.critrevonc.2026.105216","article-title":"Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: a systematic review and network meta-analysis","volume":"221","author":"Fedyanin","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e70339","DOI":"10.1002\/cncr.70339","article-title":"Review of patient-reported outcomes in EMPOWER-lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy","volume":"132","author":"Gandara","year":"2026","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1245\/s10434-026-19138-7","article-title":"Real-world long-term outcomes of first-line Pembrolizumab in advanced PD-L1 \u2265 50% NSCLC: a systematic review and meta-analysis","volume":"33","author":"Machado","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1703943","DOI":"10.3389\/fimmu.2026.1703943","article-title":"Targeting regulated cell death pathways in lung cancer: mechanisms, therapeutic strategies, and clinical translation","volume":"17","author":"Xue","year":"2026","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41571-025-01080-4","article-title":"Unresectable stage III non-small-cell lung cancer: state of the art and challenges","volume":"23","author":"Remon","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"567238","DOI":"10.2147\/ITT.S567238","article-title":"Emerging predictive biomarkers of immunotherapy sensitivity in patients with non-small cell lung cancer","volume":"15","author":"Gariazzo","year":"2026","journal-title":"Immunotargets Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1186\/s12967-025-07084-z","article-title":"Neutrophils in non-small cell lung cancer and immunotherapy with PD-1\/PD-L1 inhibitors","volume":"23","author":"Hu","year":"2025","journal-title":"J Transl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1186\/s12885-025-13822-9","article-title":"The prognostic\/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis","volume":"25","author":"Saeed","year":"2025","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11912-025-01718-7","article-title":"Host-related determinants of response to immunotherapy in non-small cell lung Cancer: the interplay of body composition, metabolism, sex and immune regulation","volume":"27","author":"Santo","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/cancers16081508","article-title":"Prognostic biomarkers of systemic inflammation in non-small cell lung cancer: a narrative review of challenges and opportunities","volume":"16","author":"Stares","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/01635581.2026.2632656","article-title":"Optimizing nutritional support in advanced non-small cell lung cancer: evidence and controversies in Oral, enteral, and parenteral approaches","volume":"78","author":"Obomanu","year":"2026","journal-title":"Nutr Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/01635581.2025.2569118","article-title":"Association between immunotherapy and overall survival in malnourished patients with advanced non-small cell lung Cancer: a Nationwide retrospective cohort study in Japan","volume":"78","author":"Shimasaki","year":"2026","journal-title":"Nutr Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5937\/jomb0-54181","article-title":"Predictive value of serum tumor markers carcinoembryonic antigen, neuron-specific enolase, and squamous cell carcinoma antigen in non-small cell lung cancer patients treated with programmed cell death protein 1 inhibitors","volume":"44","author":"Wang","year":"2025","journal-title":"J. Med Biochem"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"101142","DOI":"10.1016\/j.ctarc.2026.101142","article-title":"Durable clinical benefit and progression-free survival in patients with PD-L1 \u226550% NSCLC receiving pembrolizumab: impact of nutritional and inflammatory markers","volume":"47","author":"Yamakawa","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/1354750X.2026.2621291","article-title":"Evaluation of inflammatory parameters and ferritin as prognostic factors in non-small cell lung cancer patients receiving nivolumab immunotherapy","volume":"31","author":"Beyp\u0131nar","year":"2026","journal-title":"Biomarkers"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1186\/s12877-025-06621-1","article-title":"Trajectory subgroups and influencing factors of nutrition-related risk in older NSCLC patients undergoing chemotherapy","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Geriatr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1219929","DOI":"10.3389\/fimmu.2023.1219929","article-title":"Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"102229","DOI":"10.1016\/j.gassur.2025.102229","article-title":"Prognostic value of preoperative nutritional status in patients with gastric cancer undergoing radical gastrectomy: a comprehensive meta-analysis and multidimensional risk assessment","volume":"29","author":"Zheng","year":"2025","journal-title":"J Gastrointest Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1706534","DOI":"10.3389\/fnut.2025.1706534","article-title":"Prognostic value of prognostic nutritional index in cancer: an umbrella review of systematic review and meta-analysis","volume":"12","author":"Yang","year":"2025","journal-title":"Front Nutr"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12876-026-04702-y","article-title":"Prognostic value of the prognostic nutritional index in colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Xu","year":"2026","journal-title":"BMC Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"15283","DOI":"10.2147\/JIR.S541842","article-title":"Do inflammatory and nutritional markers predict prognosis in metastatic non-small cell lung Cancer patients receiving Nivolumab","volume":"18","author":"Zeynelgil","year":"2025","journal-title":"J Inflamm Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"35427","DOI":"10.1038\/s41598-025-19362-3","article-title":"Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy","volume":"15","author":"Hashimoto","year":"2025","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/medicina61071160","article-title":"Prognostic role of inflammatory and nutritional indices in NSCLC patients treated with immune checkpoint inhibitors: retrospective, multicenter, Turkish oncology group study of overall and elderly populations","volume":"61","author":"Alan","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1440-1681.13740","article-title":"Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy","volume":"50","author":"Fang","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e41087","DOI":"10.1097\/MD.0000000000041087","article-title":"Association of prognostic nutritional index with long-term survival in lung cancer receiving immune checkpoint inhibitors: a meta-analysis","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/nu11040826","article-title":"Effect of red, processed, and white meat consumption on the risk of gastric cancer: an overall and dose\u2212response meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Nutrients"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"102412","DOI":"10.1016\/j.eclinm.2023.102412","article-title":"Efficacy of e-health interventions for smoking cessation management in smokers: a systematic review and meta-analysis","volume":"68","author":"Li","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.62347\/XQHL4852","article-title":"Value of prognostic nutritional index and controlling nutritional status score for advanced non-small cell lung cancer patients receiving PD-1 inhibitors","volume":"14","author":"Jiang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.7150\/jca.55936","article-title":"Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors","volume":"12","author":"Liu","year":"2021","journal-title":"J Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.21037\/jtd.2020.02.27","article-title":"The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab","volume":"12","author":"Matsubara","year":"2020","journal-title":"J Thorac Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000533604","article-title":"Prognostic potential of the prognostic nutritional index in non-small cell lung Cancer patients receiving Pembrolizumab combination therapy with carboplatin and paclitaxel\/nab-paclitaxel","volume":"102","author":"Nishihara-Kato","year":"2024","journal-title":"Oncology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.esmoop.2022.100445","article-title":"Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer","volume":"7","author":"Stares","year":"2022","journal-title":"ESMO Open"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1516737","DOI":"10.3389\/fimmu.2024.1516737","article-title":"The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model","volume":"15","author":"Tang","year":"2024","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/medicina60111792","article-title":"Comparison of prognostic values of seven immune indexes in advanced non-small-cell lung cancer treated with Nivolumab: how effective can they be regarding our treatment decisions?","volume":"60","author":"Ulas","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000534169","article-title":"Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced non-small cell lung Cancer","volume":"102","author":"Yamaguchi","year":"2024","journal-title":"Oncology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"103288","DOI":"10.1016\/j.clnesp.2026.103288","article-title":"Albumin-myosteatosis gauge as predictor of survival time in patients with lung cancer treated with immune checkpoint inhibitors","volume":"73","author":"Wei","year":"2026","journal-title":"Clin Nutr ESPEN"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e71839","DOI":"10.1002\/cam4.71839","article-title":"Association between red blood cell distribution width-to-albumin ratio and breast, colorectal, lung, and prostate cancers","volume":"15","author":"Habibzadeh","year":"2026","journal-title":"Cancer Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00262-026-04364-5","article-title":"Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitors","volume":"75","author":"Yang","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e17400","DOI":"10.1016\/j.heliyon.2023.e17400","article-title":"Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"9","author":"Xia","year":"2023","journal-title":"Heliyon"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"104669","DOI":"10.1016\/j.critrevonc.2025.104669","article-title":"Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: a systematic review and meta-analysis","volume":"210","author":"Zhang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"10732748241285474","DOI":"10.1177\/10732748241285474","article-title":"Predictability of neutrophile to lymphocyte ratio and platelet to lymphocyte ratio on the effectiveness of immune checkpoint inhibitors in non-small cell lung cancer patients: a meta-analysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Cancer Control"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1859449\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:28:23Z","timestamp":1784780903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1859449\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":51,"alternative-id":["10.3389\/fnut.2026.1859449"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1859449","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1859449"}}